In this issue of JAMA, Jabbour and colleagues report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy. They found ponatinib to have superior efficacy and a comparable safety profile for frontline treatment of adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). On the heels of these results, the US Food and Drug Administration granted ponatinib accelerated approval for this indication on March 19, 2024.
